Mom Genes Fight PPD (previously called PPD Act) is a research study developed by Postpartum Depression: Action Towards Causes and Treatment (PACT) Consortium, an international group of academic clinicians and scientists committed to understanding the interaction of genes and environment to predict which women are at risk of postpartum depression (PPD).
Researchers in the Departments of Psychiatry and Genetics at the University of North Carolina at Chapel Hill who are PACT Consortium members are leading Mom Genes Fight PPD and overseeing the US arm of the study. Researchers from Queensland Brain Institute at the University of Queensland, and University of Toronto oversee the Australian and Canadian arms of the study. Teams from Aarhus University in Denmark and Uppsala and Karolinska Universities in Sweden have also joined this global project.
The UNC School of Medicine Departments of Psychiatry and Genetics sponsored the creation of the app. Within the UNC Department of Psychiatry, The team from UNC Center for Women's Mood Disorders provided the infrastructure to create the app. The UNC Center for Health Innovation provided critical project management.
The National Institute of Mental Health (NIMH) is the lead federal agency for research on mental disorder focused on transforming the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery, and cure. NIMH is partnering with PPD ACT to provide the spit kits used for DNA collection.
Postpartum Support International was founded in 1987 by Jane Honikman in Santa Barbara, California. The purpose of the organization is to increase awareness among public and professional communities about the emotional changes that women experience during pregnancy and postpartum. Approximately 15% of all women will experience postpartum depression following the birth of a child. Up to 10% will experience depression or anxiety during pregnancy. When the mental health of the mother is compromised, it affects the entire family.
SAGE Therapeutics is a neuroscience-focused company discovering medicines to treat life-threatening, rare CNS disorders. Launched in 2010, SAGE is a publicly traded company led by an experienced team of leaders, CNS experts and investors. Our lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many in an exciting portfolio of potential seizure medicines.
The Foundation of Hope promotes scientific research aimed at discovering the causes and potential cures for mental illness in order to develop a more effective means of treatment. The Foundation is committed to raising community awareness and supporting effective treatment programs. The Foundation provides financial support for ongoing and new research and treatment, as well as the development of researchers at the University of North Carolina at Chapel Hill, its affiliated psychiatric institutions, and local mental health agencies.
A custom software solutions expert offering clients award-winning intuitive user experiences.
A human experience company that uses insights, creativity and data to make brands matter to customers.